Research programme: therapeutics for neuropsychiatric and neurodevelopmental disorders - AstraZeneca/Lieber Institute for Brain Development
Latest Information Update: 16 Dec 2013
At a glance
- Originator AstraZeneca; Lieber Institute for Brain Development
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mental disorders
Most Recent Events
- 03 Dec 2013 Early research in Mental disorders (neuropsychiatric and neurodevelopmental disorders) in USA (PO)